Here are four things to know.
1. The treatment is a combination of Verzenio, an already FDA-approved medication, and an aromatase inhibitor.
2. It is approved for the treatment of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer.
3. The approval is the third expanded approval for Verzenio in the last five months.
4. “This approval is an important milestone, as it shows that Verzenio plus an aromatase inhibitor substantially reduced tumor size and delayed disease progression in women with HR+, HER2- metastatic breast cancer,” Eli Lilly said in a press release.
More articles on supply chain:
Why a better hospital supply chain starts with better relationships
Teva shutters offices in New York City, Washington D.C., as part of cost cutting plan
Walgreens, AmerisourceBergen reportedly end takeover discussions with no deal
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.